Differential control of Helios+/-Treg development by monocyte subsets through disparate inflammatory cytokines

Blood

Volumn 121, Issue 13, 2013, Pages 2494-2502

  Zhong, Hui ^a   Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR HELIOS; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; AUTACOID; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IKAROS TRANSCRIPTION FACTOR; IKZF2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL EXPANSION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; DRUG EFFECT; GENETICS; HETEROZYGOTE; IMMUNOLOGY; LYMPHOPOIESIS; METABOLISM; PHYSIOLOGY;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; GPI-LINKED PROTEINS; HETEROZYGOTE; HUMANS; IKAROS TRANSCRIPTION FACTOR; INFLAMMATION MEDIATORS; INTERLEUKIN-12; LYMPHOPOIESIS; MONOCYTES; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84878417340     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-469122     Document Type: Article

References (47)

1. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP31 regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7): 490-500.
2. Fu W, Ergun A, Lu T, et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol. 2012;13(10):972-980.
3. Getnet D, Grosso JF, Goldberg MV, et al. A role for the transcription factor Helios in human CD4(1)CD25(1) regulatory T cells. Mol Immunol. 2010;47(7-8):1595-1600.
4. Kim YC, Bhairavabhotla R, Yoon J, et al. Oligodeoxynucleotides stabilize Heliosexpressing Foxp31 human T regulatory cells during in vitro expansion. Blood. 2012;119(12): 2810-2818.
5. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymicderived from peripherally induced Foxp31 T regulatory cells. J Immunol. 2010;184(7): 3433-3441.
6. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp31 regulatory T cells. J Immunol. 2012;188(3): 976-980.
7. Akimova T, Beier UH, Wang L, et al. Helios expression is a marker of T cell activation and proliferation. PLoS ONE. 2011;6(8):e24226.
8. Redjimi N, Raffin C, Raimbaud I, et al. CXCR31 T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 2012;72(17): 4351-4360.
9. Elkord E, Al-Ramadi BK. Helios expression in FoxP3(1) T regulatory cells. Expert Opin Biol Ther. 2012;12(11):1423-1425.
10. Wang C, Lee JH, Kim CH. Optimal population of FoxP31 T cells in tumors requires an antigen priming-dependent trafficking receptor switch. PLoS ONE. 2012;7(1): E30793.
11. Wainwright DA, Sengupta S, Han Y, et al. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-oncol. 2011;13(12):1308-1323.
12. Elkord E, Sharma S, Burt DJ, et al. Expanded subpopulation of FoxP31 T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol. 2011;140(3): 218-222.
13. Li CW, Zhang KK, Li TY, et al. Expression profiles of regulatory and helper T-cell-associated genes in nasal polyposis. Allergy. 2012;67(6):732-740.
14. Hatam LJ, Devoti JA, Rosenthal DW, et al. Immune suppression in premalignant respiratory papillomas: Enriched functional CD41Foxp31 regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res. 2012;18(7):1925-1935.
15. McGovern JL, Nguyen DX, Notley CA, et al. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 2012;64(10): 3129-3138.
16. Xu WH, Zhang AM, Ren MS, et al. Changes of Treg-associated molecules on CD41CD25 1Treg cells in myasthenia gravis and effects of immunosuppressants. J Clin Immunol. 2012; 32(5):975-983.
17. McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011;186(7):3918-3926.
18. Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: Relationship with metabolic factors and complications. J Mol Med (Berl). 2012;90(2): 175-186. [Berl]
19. Zhen Y, Sun L, Liu H, et al. Alterations of peripheral CD41CD251Foxp31 T regulatory cells in mice with STZ-induced diabetes. Cell Mol Immunol. 2012;9(1):75-85.
20. Neill DR, Fernandes VE, Wisby L, et al. T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog. 2012;8(4):e1002660.
21. Reynolds LA, Maizels RM. Cutting edge: In the absence of TGF-b signaling in T cells, fewer CD1031 regulatory T cells develop, but exuberant IFN-g production renders mice more susceptible to helminth infection. J Immunol. 2012;189(3):1113-1117.
22. Tang Q, Leung J, Melli K, et al. Altered balance between effector T cells and FOXP3(1) HELIOS(1) regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl. Int. 2012; 25(12):1257-1269.
23. Fujimoto M, Nakano M, Terabe F, et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp31 regulatory T cells. J Immunol. 2011;186(1):32-40.
24. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-692.
25. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375-386.
26. Zhong H, Bao W, Li X, et al. CD161 monocytes control T-cell subset development in immune thrombocytopenia. Blood. 2012;120(16): 3326-3335.
27. Boissier MC, Assier E, Biton J, et al. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine. 2009;76(1):10-14.
28. Nagar M, Jacob-Hirsch J, Vernitsky H, et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol. 2010;184(7):3570-3581.
29. Bilate AM, Lafaille JJ. Can TNF-a boost regulatory T cells?. J Clin Invest. 2010;120(12): 4190-4192.
30. Grinberg-Bleyer Y, Saadoun D, Baeyens A, et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest. 2010;120(12): 4558-4568.
31. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA. 1990;87(8): 3127-3131.
32. Zhao J, Zhao J, Perlman S. Differential effects of IL-12 on Tregs and non-Treg T cells: Roles of IFN-g, IL-2 and IL-2R. PLoS ONE. 2012;7(9): E46241.
33. Feng T, Cao AT, Weaver CT, et al. Interleukin-12 converts Foxp31 regulatory T cells to interferong- producing Foxp31 T cells that inhibit colitis. Gastroenterology. 2011;140(7):2031-2043.
34. Koch MA, Thomas KR, Perdue NR, et al. T-bet(1) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor b2. Immunity. 2012;37(3): 501-510.
35. O'Malley JT, Sehra S, Thieu VT, et al. Signal transducer and activator of transcription 4 limits the development of adaptive regulatory T cells. Immunology. 2009;127(4):587-595.
36. Liu J, Cao S, Kim S, et al. Interleukin-12: An update on its immunological activities, signaling and regulation of gene expression. Curr Immunol Rev. 2005;1(2):119-137.
37. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNFalpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204(1): 33-39.
38. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12): 953-964.
39. Kawanaka N, Yamamura M, Aita T, et al. CD141, CD161 blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2002; 46(10):2578-2586.
40. Jin J, Chang Y, Wei W. Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol Sin. 2010;31(9):1133-1140.
41. Zaghi D, Krueger GG, Callis Duffin K. Ustekinumab: A review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol. 2012;11(2):160-167.
42. Roberts NJ, Zhou S, Diaz LA Jr, et al. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget. 2011;2(10):739-751.
43. Weiss JM, Subleski JJ, Wigginton JM et al. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther. 2007;7(11):1705-1721.
44. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: They are all the same (aren't they?). Rheumatology (Oxford). 2005;44(3):271-273.
45. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3): 1548-1561.
46. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell. 2001;104(4):487-501.
47. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012; 24(6):1297-1305.